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Abstract
Background: Protozoan parasites, such as Leishmania, still pose an enormous public health problem in many countries
throughout the world. Current measures are outdated and have some associated drug resistance, prompting the search into
novel therapies. Several innovative approaches are under investigation, including the utilization of host defence peptides
(HDPs) as emerging anti-parasitic therapies. HDPs are characterised by their small size, amphipathic nature and cationicity,
which induce permeabilization of cell membranes, whilst modulating the immune response of the host. Recently, members
of the cathelicidin family of HDPs have demonstrated significant antimicrobial activities against various parasites including
Leishmania. The cathelicidin bovine myeloid antimicrobial peptide 28 (BMAP-28) has broad antimicrobial activities and
confers protection in animal models of bacterial infection or sepsis. We tested the effectiveness of the use of BMAP-28 and
two of its isomers the D-amino acid form (D-BMAP-28) and the retro-inverso form (RI-BMAP-28), as anti-leishmanial agents
against the promastigote and amastigote intracellular Leishmania major lifecycle stages.
Methodology/Principal Findings: An MTS viability assay was utilized to show the potent antiparasitic activity of BMAP-28
and its protease resistant isomers against L. major promastigotes in vitro. Cell membrane permeability assays, caspase 3/7,
Tunel assays and morphologic studies suggested that this was a late stage apoptotic cell death with early osmotic cell lysis
caused by the antimicrobial peptides. Furthermore, BMAP-28 and its isomers demonstrated anti-leishmanial activities
against intracellular amastigotes within a macrophage infection model.
Conclusions/Significance: Interestingly, D-BMAP-28 appears to be the most potent antiparasitic of the three isomers
against wild type L. major promastigotes and amastigotes. These exciting results suggest that BMAP-28 and its protease
resistant isomers have significant therapeutic potential as novel anti-leishmanials.
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Introduction
The protozoan parasite Leishmania, the causative agent of
leishmaniasis, represents a global health problem that is prevalent
inEurope,Africa,AsiaandtheAmericas.Upto20millionpeopleare
affected [1]. Leishmaniasis presents one of three distinct categories of
diseases; visceral, cutaneous and mucocutaneous. Visceral leishman-
iasis is the most severe form of the disease; it causes a chronic
disseminating disease of the liver and spleen, and can be fatal if left
untreated [2]. Thecutaneousdisease generallypresentsasself-healing
cutaneous lesions; however, with certain species can subsequently
metastasize resulting in debilitating mucocutaneous disease [2].
Leishmania have a digenetic lifecycle consisting of the morpholog-
ically distinct promastigote and amastigote stages. The motile
flagellatedstage,thepromastigoteform,resideextracellularlyinsand
fly vectors of the genera Phlebotomus or Lutzomyia [3]. Virulent
metacyclic promastigotes are inoculated into the dermis of
mammalian hosts during sand fly blood meals. Macrophages rapidly
internalize the promastigotes into a parasitophorous vacuole, which
fuses with lysosomes to generate an acidic compartment containing
hydrolytic enzymes. This triggers differentiation into the aflagellated
obligateintracellularstage,theamastigote,whichinitatestheonsetof
disease symptoms in the host [4].
Traditional drug treatments consisit of polyvalent antimonial
therapy; repeated infections of the human population by either
zoonotic or anthroponotic cycles coupled with ineffective treat-
ments have led to selection of antimony-resistant parasites that
may cycle through the human reservoirs leading to increase drug
resistance within populations [5]. Furthermore, the efficacy of
leishmaniasis therapeutics has also been threatened by the growing
www.plosntds.org 1 May 2011 | Volume 5 | Issue 5 | e1141incidence of multidrug resistance [6,7], emphasizing the need for
novel therapies. In the search for novel anti-infective therapies host
defence peptides (HDPs), evolutionarily conserved defence mole-
cules found in all living species, are an intriguing alternative.
HDPs are central components of the defence mechanisms of
organisms ranging from bacteria to animals. These peptides are
defined by their amphipathic nature, cationicity and relatively
small size. The cationicity and hydrophobic nature of HDPs
promote their interaction with cell membranes and in particular
the negatively charged membranes of Gram-positive and Gram-
negative bacteria. Although the antimicrobial activity of HDPs
was initially attributed directly to cell membrane lysis, HDPs can
also translocate across cell membranes and interact with various
internal microbial targets such as DNA [8,9] and DnaK [10,11].
Indeed, the translocation of HDPs across eukaryotic cell
membranes and subsequent interaction with cell vacuoles has also
been demonstrated [12]. Thus, in addition to their direct
antimicrobial activities, there is an emerging appreciation for the
ability of HDPs to modulate host immune responses. These
immunomodulatory activities include the up-regulation of cyto-
kines/chemokines and their receptors, leukocytes recruitment,
stimulation of histamine release from mast cells, angiogenesis,
dendritic cell maturation, wound healing, and the ability to
modulate the potentially pathological inflammation that can be
associated with bacterial infection (sepsis) [13,14,15,16,17,18].
These HDP activities include anti-protozoan and anti-leishmanial
activities [12,19,20,21,22]. Furthermore, the pleotropic activities
of HDPs make them compelling templates for the development of
novel anti-infective therapeutics.
Recently, bovine myeloid antimicrobial peptide 28 (BMAP-28),
a cathelicidin found in bovine neutrophils, has been demonstrated
to confer protection to bacterial infection and sepsis in animals
[23,24]. BMAP-28 has also been demonstrated to initiate the
depolarization of mitochondrial membranes via the induction of
the mitochondrial permeability transition pore [25].
The therapeutic potential of BMAP-28 may be limited based on
its in vitro toxicity. However, our recent data has demonstrated that
the D- amino acid enantiomer of BMAP-28 and retro-inverso (RI)-
BMAP-28, in which all L- amino acids of the parent peptide are
replaced by D- amino acids along with reversal of the order of the
peptide sequence, may remove these limitations [26]. Previous
investigations of various antimicrobial peptides have also demon-
strated that enantiomeric replacements significantly reduced hemo-
lytic activity without affecting antimicrobial activity [26,27,28,29].
Thus, BMAP-28 and its protease resistant isomers are intriguing
candidatesfortestingoftherapeuticpotentialagainstLeishmaniamajor.
In this study, L-BMAP-28, D-BMAP-28 and RI-BMAP-28 were
shown to be effective therapeutics against Leishmania promastigotes
in vitro with the D- isoform being most effective in reducing
promastigote viability. Cell membrane integrity was disrupted
upon BMAP-28 interaction, inducing a late stage apoptotic cell
death response. Interestingly, the BMAP-28 peptides were also
effective at reducing amastigote cell viability within a macrophage
infection model. This data convincingly demonstrates that BMAP-
28 isoforms D- and RI-BMAP-28 are promising candidates for
anti-leishmanial therapies.
Materials and Methods
Ethics Statement
All subjects who participated in this study provided informed
consent in writing according to the University of British Columbia
Clinical Research Ethics Board guidelines and approval.
Cell lines
Leishmania major strains Friedlin (MHOM/IL/80/Friedlin) and
Seidman (NHOM/SN/74/Seidman, denoted as wt), its leishma-
nolysin knockout derivative (denoted as ko) and the back
leishmanolysin transfected line (denoted ko+) [20,30] were used
in these studies. These cells were routinely cultured at 26uCi nM -
199 medium (Gibco, Grand Island, NY), supplemented with 10%
heat inactivated fetal calf serum (Hyclone, Logan) and Pen/Strep
(Gibco, Grand Island, NY).
THP-1 cells were routinely cultured with DMEM, supplemented
with 10% heat inactivated fetal calf serum (Hyclone, Logan), and
2 mM L-glutamine and Pen/Strep (Gibco, Grand Island, NY).
Peptide synthesis
BMAP-28 (GGLRSLGRKILRAWKKYGPIIVPIIRIG) iso-
mers were chemically synthesized on a Pioneer solid-phase peptide
synthesizer (PerSeptive Biosystems, Foster City, CA) using Fmoc
(9-fluorenylmethoxy carbonyl) chemistry. The peptide chains were
synthesized from the carboxyl terminus to the amino terminus
onto [5-(4-Fmoc-aminomethyl-3,5-dimethyloxyphenoxy) valeric
acid]-polyethylene glycol-polystyrene (PAL-PEG-PS) resin. Fmoc-
protecting groups at the amino terminus were deprotected with
piperidine. The peptides were cleaved from the resin with
concurrent deprotection of the side chain-protecting groups by
treating the resin-bound peptide with trifluoroacetic acid (TFA)
(9.3 parts) in the presence of scavengers (anisole-ethyl-methyl
sulfide-1,2-ethanedithiol [3:3:1]), for 7 hours. The crude peptides
were filtered from the resin, and the TFA was evaporated. Diethyl
ether was added to the residues to precipitate the crude peptide.
The peptides were isolated and purified by high-performance
liquid chromatography (HPLC) on Vydac protein C4 columns (1.0
by 25 cm) eluting with a linear gradient of 10% buffer A (H2O-
0.1% TFA)-90% buffer B (acetonitrile-H2O [90/10]-0.01% TFA)
for 40 min at a flow rate of 3 ml/minute. Fractions of greater than
95% purity were used for the investigation. The purity and
Author Summary
Protozoan parasites are the causative agent of much
disease in tropical areas of the world. Currently, the control
of these diseases is dependent on outdated drug
treatment, with associated high toxicity and drug resis-
tance. There is an urgent need for novel anti-parasitic
therapies. One emerging anti-parasitic therapies is Host
defence peptides (HDPs). Here we test the HDP BMAP-28
as an anti-leishmanial therapy against two lifecycle stages
of Leishmania major, the promastigotes (insect infective
form) and the intracellular amastigote (mammalian infec-
tive form). Two stereoisomers of BMAP-28, the D-amino
acid form (D-BMAP-28) and the retro-inverso form (RI-
BMAP-28), were also tested for anti-leishmanial activity.
The BMAP-28 form (L-form) was susceptible to degrada-
tion by GP63, the metalloproteinase that covers the
promastigotes cell surface. However, the BMAP-28 isomers,
the D-form and RI-form were resistant, and therefore more
potent against the promastigote parasite. Though other
anti-leishmanial HDP studies focus on the promastigote
form of the parasite, it is the mammalian infective form,
the amastigote, which causes the disease symptoms. Here
we demonstrate that BMAP-28 and its isomers D-BMAP-28
and RI-BMAP-28 are effective against the amastigote form
of the parasite using a macrophage infection model. These
findings show that BMAP-28 has excellent potential as a
novel anti-leishmanial therapeutic.
Effect BMAP-28 Peptides on Leishmania major Growth
www.plosntds.org 2 May 2011 | Volume 5 | Issue 5 | e1141molecular weight of the respective peptides were confirmed by
matrix-assisted laser desorption ionization (MALDI)-time of flight
mass spectrometry on a PE Biosystems Voyager system 4068
(National Research Council, Plant Biotechnology Institute,
Saskatoon, Canada) and by amino acid analysis.
Peptide preparation
The BMAP-28 peptides were reconstituted in sterile H2O
(Sigma) at 1 mM concentrations. Working stocks were generated
from this stock at 0.5 mM and 2 mM concentrations in an
appropriate medium.
Preparation of MTS solutions
A solution of {3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethox-
yphenyl)-2-(4-sulfophenyl}-2H-tetrazolium, inner salt or MTS
(Promega, Madison, WI, USA) was prepared (2 mg/ml in
phosphate-buffered saline 0.02 M, pH 7.2, PBS) and stored at
220uC. Phenazine methosulphate (PMS, 0.92 mg/ml) (Sigma-
Aldrich, St. Louis, MI, USA) was similarly prepared in PBS
(0.02 M, pH 7.2) and stored at 220uC. Both solutions were stored
in the dark and combined just prior to use.
MTS assay
Mid-log phase promastigotes at concentrations of 5610
6 per
100 ml/well were seeded in 96-well tissue culture plates. Peptides
were added to the cells in volumes of 20 ml. Heat-killed parasites,
prepared by incubation at 99uC for 30 minutes, served as negative
controls for the MTS assay. Peptides (0.5 or 2 mM) were incubated
with the cells for 4 hours. MTS/PMS was combined 5:1, and
20 ml was added to each well and incubated at 37uC for 3 hours.
Absorbances at 490 nm were measured using a plate reader
(Versamax, Molecular devices, US).
Electron microscopy
Following HDP incubation for 4 hours, promastigote parasites
were washed twice in PBS, fixed in 5% (w/v) glutaraldehyde in
PBS, included incubated with 2.5% (w/v) OsO4 for 1 hour,
gradually dehydrated in ethanol (30, 50, 70, 90, and 100% [v/v];
30 min each) and propylene oxide (1 hour), embedded in Epon
812 resin, and observed using a Hitachi H7600 transmission
electron microscope (Hitachi, Tokyo, Japan).
SYTOX assay
The SYTOX green assay for cell membrane permeability has
been previously described [21]. Briefly, 10
7 mid-log phase
parasites were washed twice in PBS then incubated in the dark
with 1 mM SYTOX Green (Promega) in PBS for 15 minutes.
Fluorescence was measured every 5 minutes after peptide addition
for up to 2 hours in a microplate reader, with excitation and
emission wavelengths of 485 and 520 nm, respectively. The
maximum fluorescence control was demonstrated by the addition
of 0.5% Triton X-100.
Caspase assay
5610
6 mid-log phase Leishmania cells were incubated with 2 mM
D-BMAP-28 or 16 mM staurosporine (Sigma-Aldrich, Oakville,
Ontario) for various time intervals at 26uC. Caspase 3/7 protease
activity was assayed using the Apo-ONE Homogeneous Caspase-
3/7 Assay kit (Promega).
TUNEL assay
5610
6 mid-log phase Leishmania cells were incubated with 2 mM
D-BMAP-28 for various time intervals at 26uC. Leishmania cells
were treated with Staurosporine (16 mM; Sigma-Aldrich) for 24 hr
at 26u. Quantitation of double stranded DNA breaks was assayed
using the HT TiterTACS Assay Kit (Trevigen, Gaithersburg,
MD). The following modifications to the manufacturer’s instruc-
tions were made: all centrifugation steps were done at 78406g for
10 min each, fixation was done in 4% Paraformaldehyde for
10 min and DNase was incubated with cell lysate for 60 min at
37uC to generate the positive control. A total cell number of
5610
6 was used for each labeling reaction. The labeling reaction
was done in individual centrifugation tubes.
Murine macrophage cell viability assay
THP-1 cells were seeded into 100 ml volumes at 1610 5 cells/
ml. Cell were incubated in the presence of 5 or 20 mMo fL -
BMAP, Ri-BMAP and D-BMAP to a final concentration of 1 or
5 mM for 24 or 72 hours respectively. The THP-1 cell viability was
assessed by the addition of trypan blue (Sigma aldrich) on a
hemacytometer (Table S1) [31].
Amastigote assay
Peritoneal macrophages were isolated from 4 to 6 week old
BALB/c mice by peritoneal lavage in accordance UBC animal
care committee. After isolation, macrophages were washed once
with 5 ml complete RPMI medium (Gibco) containing 100 units/
ml Penicillin/Streptomycin and resuspended in RPMI medium
supplemented with 10% fetal bovine serum (FBS) (Hyclone,
Logan, USA). 2610
5 peritoneal macrophages were seeded into
wells of a 24 well plate (Falcon) in a 500 ml volume of complete
RPMI medium and allowed to adhere to the coverslips overnight
at 34uCi n5 %C O 2. Infections were performed routinely at a ratio
of 10 parasites per macrophage. Briefly, macrophages were
infected with day 4 stationary phase promastigotes for 4 hours,
washed 3 times with RPMI medium, and subsequently cultured in
complete RPMI medium for 48 hours. Cells were incubated with
200 ml of 0.5 or 2 mM concentrations of L-, RI- or D-BMAP-28
for 24 hours. Subsequently, macrophages were fixed by incuba-
tion in 10% formaldehyde/PBS at room temperature for
10 minutes, permeabilised in 100% methanol for 20 minutes
and stained with ProLong Gold antifade reagent with DAPI
(Invitrogen, Eugene, USA). The slides were viewed under UV light
with an upright fluorescent microscope (Zeiss, Oberkochen,
Germany). Images were collected from the microscope with
Digital Focus software and parasite burden per macrophage was
quantified as an average of 100 macrophages, and expressed as a
percentage of the control infection.
Immunomodulatory activities of L-, D- and RI-BMAP-28
Human venous blood (100 ml) was collected from healthy
volunteers in Vacutainer collection tubes containing heparin (Cat
No. 362753, BD, Franklin Lakes, NJ). Blood was mixed at a 1:1
ratio with RPMI 1640 medium (supplemented with 10% (v/v)
FBS, 2 mM L-glutamine, and 1 mM sodium pyruvate) and the
peripheral blood mononuclear cells (PBMC) were separated by
centrifugation in Ficoll-Paque
TM PLUS (Cat No. 17-1440-02, GE
Healthcare). Peripheral blood mononuclear cells (PBMCs) were
isolated from the buffy coat, washed twice in sterile PBS and the
numbers of live cells were determined by trypan blue exclusion.
PBMCs (0.1 ml at 1610
6 cells/ml) were seeded into 96-well tissue
culture dishes (Sarstedt), incubated at 37uCi n5 %C O 2 in air and
rested for 2 hours before experimental treatment.
To measure cytokine stimulation, PBMCs were treated for
24 hours with L-, D-, and RI-BMAP-28. Monocyte chemotactic
protein-1 (MCP-1) was measured in culture supernatants using
ELISAs (see below). To test for anti-endotoxin activity, PBMCs
Effect BMAP-28 Peptides on Leishmania major Growth
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addition of 10 ng/ml of purified Pseudomonas aeruginosa LPS for
4 hours. P. aeruginosa LPS was purified as described previously
[32]. After 4 hours, secreted TNF-a was measured by ELISA (see
below).
Following peptide stimulation for 24 hours, the tissue culture
supernatants were centrifuged at 16,0006g (13,000 rpm) at 4uC
for 5 minutes in an IEC MicroMax centrifuge to obtain cell-free
samples. Supernatants were aliquoted and then stored at 220uC.
Secretion of MCP-1 into the tissue culture supernatants was
detected by sandwich ELISA (BioSource International and
eBiosciences, respectively) (Figure S1). All assays were performed
in triplicate. MCP-1 concentration in the culture medium was
quantified by establishing a standard curve with serial dilutions of
the recombinant human MCP-1. Secretion of TNF-a was
monitored in rested PMBCs and cells exposed to peptide and/or
LPS (P. aeruginosa) by capture ELISA after 24 hrs (eBiosciences).
Results
BMAP-28 effects L. major promastigote cell viability in a
concentration dependent manner
To test the anti-leishmanial activities of the BMAP-28 variants,
specifically the effects on the viability of promastigote L. major
Friedlin, an MTS viability assay was performed. An MTS assay
measures the mitochondial dehydrogenase levels of viable cells.
Unmodified peptide (L-BMAP-28), the retro-inverso isoform (RI-
BMAP-28) and the D- amino acid isoform (D-BMAP-28) were
incubated with L. major Friedlin promastigotes in vitro (Figure 1a).
Cell viability was assessed at 490 nm and expressed as a
percentage of the untreated control. Cells remained 100% viable
upon treatment with 0.5 mM L- and RI-BMAP-28, but experi-
enced a 30% reduction in cell viability when treated with D-
BMAP-28. Upon addition of 2 mM concentrations of the HDPs,
the HDPs demonstrated a concentration dependent effect on L.
major Friedlin. Cell viability was reduced to 60%, 20% and 5%
when treated with L-, RI- and D-BMAP-28, respectively. Of the
three BMAP-28 variant forms, the D- form of the peptide was the
most potent.
The effect of protease resistant L-, RI- and D-BMAP-28 on
leishmanolysin ko Leishmania promastigotes
Previously, the surface metalloprotease leishmanolysin was
demonstrated to bestow increased resistance to the antimicrobial
activities of HDPs in L. major [21]. As RI-BMAP-28 and D-
BMAP-28 retained leishmanicidal activity and would be hypoth-
esized to be leishmanolysin resistant we tested the antiparasitic
activity of all three BMAP-28 isomers against a leishmanolysin ko
strain of L. major Seidman strain, which lacks the GP63 surface
metalloprotease. L. major Seidman wild-type (wt), L. major ko and L.
major ko+ (reconstituted version of the Seidman strain, which
confers the wild-type phenotype [20,30]) were incubated with 0.5
and 2 mM L-, RI- and D-BMAP-28 for 4 hours and cell viability
was assessed using an MTS viability assay [33].
At both 0.5 and 2 mM concentrations, D-BMAP-28 was the
most effective of the three peptides at reducing the cell viability of
the L. major wt strain (Figure 1b). Though both RI- and D-BMAP-
28 remained at similar levels in wild-type, the L- variant was more
effective against L. major ko than wt strains (Figure 1b). Upon re-
introduction of the protease to the cells, L. major ko+, cell viability
levels reverted back to levels similar to wild-type cells; suggesting
that in absence of the GP63 protease the L- form of the peptide
was more effective at reducing the cell viability, as has been
demonstrated for other cathelicidins [20]. However, the effects of
the RI- and D- isomers of BMAP-28 on cell viability did not
change between L. major wt and ko strains, demonstrating that they
are unaffected by the proteolytic activities of leishmanolysin.
BMAP-28 analogues induce morphological changes in L.
major
To assess morphological changes induced by the BMAP-28
isomers, L. major wild-type promastigotes were incubated with
0.5 mM L-, RI- and D-BMAP-28 peptides and prepared for
transmission electron microscopy analysis (Figure 2a, b). Cell
morphologies were examined based on criterion predictive of
osmotic cell lysis: disrupted membrane, loss of cytosol and presence
of numerous large empty vacuoles. The results suggested that cells
underwent an osmotic cell lysis and followed a similar trend to the
MTS viability assay. Cell morphologies were less severe effected in
L-BMAP-28 treated cells, and increasingly severe in RI- and D-
BMAP-28 treated cells. B-MAP-28 treated cells showed significant
cell membrane disruption, losses to cytoplasmic intensity as
compared to the untreated cells and significant swelling of
cytoplasmicvacuoles(see alsoFigureS2). This severemorphological
change was likely due to osmotic cell lysis and was similar to that
seen for other HDPs such as histatin-5 [12].
BMAP-28 triggers a late apoptotic caspase-independent
mechanism of action
Recently, Kulkarni et al., have demonstrated that the HDPs
invoke a programmed cell death response in Leishmania [21]. They
have demonstrated that protegrin, a HDP of the cathelicidin class,
induced a non-apoptotic response, whilst pexiganan, a HDP of the
magainin class, induced an apoptotic mechanism of cell death
[21]. They utilized a SYTOX assay, annexin V staining, and a
caspase 3/7 assay in addition to Tunnel assays to determine
whether apoptosis was initiated. In this investigation we also
sought to determine whether BMAP-28 and its enantiomeric and
RI- analogues also followed a similar mechanism of anti-
leishmanial activity, to this end we carried out a SYTOX assay,
caspase 3/7 assay and a Tunel assay.
To examine cell membrane permeability we utilized a SYTOX
assay, whereby a SYTOX dye enters cells following membrane
disruption and fluoresces upon interaction with DNA. Wild-type,
ko and ko+ leishmanial lines were incubated with 0.5 mM and
2.0 mM of L-, D- and RI-BMAP-28 for 150 minutes in the
presence of SYTOX (Figure 3). All three cell lines treated with
0.5% Triton X-100 had an immediate rapid and sustained influx
of SYTOX. All BMAP-28 analogues demonstrated rapid
membrane permeabilization of the wt cell line at 2 mM; however,
similar permeabilization at 0.5 mM was retained only for D-
BMAP-28. In contrast, removal of the GP63 protease (ko cell line)
resulted in the highest fluorescence of the SYTOX dye, following
incubation of the cells with 2 mM L-BMAP-28 (Figure 3b).
Reconstitution of GP63 (ko+) however, resulted in HDP-mediated
membrane permeabilization phenotype similar to those found for
the wt cells (Figure 3c).
Subsequently, we investigated the caspase activity using a
caspase 3/7 assay. L. major wt, ko and ko+ cells were incubated with
2 mM D-BMAP-28 for various time intervals (,4 hr) and analyzed
for caspase 3/7 activation (Figure 4). All three cell lines had
minimal levels of caspase 3/7 activation in comparison to the
induced caspase dependent apoptotic control, staurosporine. Of
these minimal caspase 3/7 activation levels, L. major ko consistently
had the lowest level compared to wt and ko+. From these results it
was clear that the early D-BMAP-28 induced a caspase
independent cell death.
Effect BMAP-28 Peptides on Leishmania major Growth
www.plosntds.org 4 May 2011 | Volume 5 | Issue 5 | e1141Finally, we utilised a Tunel assay to investigate another aspect of
apoptosis, DNA degradation in the form of DNA laddering. L.
major wt, ko and ko+ cells were treated with 2 mM D-BMAP-28 for
time intervals ,4 hrs and at 24 hr using the TUNEL assay
(Figure 5). Cells were consistently non-apoptotic at time intervals
,4 hrs, however, upon 24 hrs incubation DNA laddering was
detected and cells designated as apoptotic. D-BMAP-28 produced
similar readouts to both apoptotic controls; staurosporine and
Figure 1. MTS viability assay of Leishmania major strains when treated with BMAP-28 variants. (A) L. major Friedlin strain was treated with
0.5 mM and 2 mM concentrations of L-, RI- and D-BMAP-28 for 4 hours. (B) L. major Seidman strain wild-type (wt, filled bars), GP63 knockout (ko, clear
bars) and reconstituted (ko+, grey bars) were treated with 0.5 mM and 2 mM concentrations of L-, RI- and D-BMAP-28 for 4 hours. Cell viability was
assessed at 490 nm and expressed as a percentage of untreated control cells. Three complete biological replicates were performed and the standard
errors are shown. Paired T-tests untreated vs treated indicated significance, where *p,0.05, **p,0.005, ***p,0.0005. The bar graph was created
using GraphPad prism 4.
doi:10.1371/journal.pntd.0001141.g001
Effect BMAP-28 Peptides on Leishmania major Growth
www.plosntds.org 5 May 2011 | Volume 5 | Issue 5 | e1141Figure 2. Analyses of effect of BMAP-28 peptides on L. major cells. (A) Wild-type cells were (i) untreated or treated with (ii) L-BMAP-28, (iii) RI-
BMAP-28 or (iv) D-BMAP-28 at 0.5 mM concentrations for 4 hours prior to fixation for TEM analyses. The figure shows cross-sections of cells at
620,000. Notice that the untreated cell has an intact membrane, an intact cytosol and a few small vacuoles. The treated cells however possess
disrupted membranes, large fluid filled vacuoles and loss of cytosolic contents; indicative of osmotic lysis. (B) Quantitative analyses of intact (clear)
versus damaged (filled) cells were carried out on wt cells in presence/absence of treatment to assess the extent of the damage. Damage was assessed
based on three criterion, membrane disruption, loss of cytosolic contents and presence of large fluid filled vacuoles, 120 cells were analysed by TEM
for each condition.
doi:10.1371/journal.pntd.0001141.g002
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the three strains, were levels were consistently higher in ko and ko+
cells.
L. major amastigotes are killed by BMAP-28 isomers in a
concentration dependent manner
In the course of these studies the BMAP-28 peptides
demonstrated anti-parasitic activity against the promastigote stage
of the parasite, however, activity against the morphological and
biochemically differentiated amastigote form has not been shown.
As the amastigote stage is the disease-causing stage of the parasite,
it is essential for further therapeutic development that the peptides
are also active against the amastigote stage. To assess the anti-
amastigote activity of the peptides an assay was created where
peritoneal-derived mouse macrophages were infected with the L.
major wt, ko and ko+ strains and subsequently treated with the
BMAP-28 peptides at 0.5 and 2 mM concentrations. Following
treatment with 0.5 mM peptide, L. major wt amastigote burdens in
the infected macrophages were inhibited by 35%, 34% and 32%
for L-, D- and RI-BMAP-28, respectively. Treatment with 2 mM
concentrations of peptides further reduced amastigote burden by
82%, 80% and 67% for L-, RI- and D-BMAP-28, respectively.
These data demonstrated that the amastigotes were killed upon
the addition of the BMAP-28 isomers in a concentration
dependent manner (Figure 6a and b).
Subsequently, this experiment was repeated using the L. major
leishmanolysin ko strain to infect the macrophages, to investigate
whether the absence of the leishmanolysin factor would play a role
in the HDP effectiveness. As GP63 is down-regulated substantially
in amastigotes, no significant differences were expected with
regards to their anti-leishmania activity between the L-, RI- and
D- forms of the peptide. As expected, there were no significant
differences in killing activity between the L- form and the protease
resistant RI- form of the peptide (Figure 6a and b). However, the
D- form of the peptide was shown to be most effective at reducing
the number of L. major ko amastigotes upon treatment with 0.5 mM
D-BMAP-28. This differs dramatically from the wt infection where
treatment of 0.5 mM D-BMAP-28 resulted in only 30% inhibition,
demonstrating that the D-isoform of BMAP-28 was again more
effective against the parasite.
Discussion
Leishmania presents a prevalent protozoan parasite causing
serious epidemics in the absence of adequate controls measures,
and ineffective and outdated drug treatments. Novel leishmanici-
dal treatments are urgently required to combat this parasite.
Ideally, these therapeutics would be pleotropic in their functions
with both direct and selective leishmanicidal effects against the
intracellular amastigote forms, as well as the ability to modulate
the immune response of the host [34].
The potential of host defence peptides (HDPs) as novel anti-
infective therapeutics has been derived from their role in nature to
combat infectious agents within all living organisms through direct
and/or indirect activities. Previously, several amphibian HDPs
including magainin, temporin, dermaseptin, bombinin, and
cecropin-melittin hybrid peptides have been shown to kill
Leishmania by disruption of cell surface membranes resulting in
osmotic lysis of the parasites [22,35,36,37,38,39]. Similarly, the
HDP histatin-5 (Hst5) has been shown to target the mitochondria
of fungi and Leishmania [12]. Indeed, other mammalian cathe-
licidins such as protegrin-1 and BMAP-27 possess significant anti-
Figure 3. Leishmania cell membrane permeabilization by L-, D- and RI-BMAP-28. L. major cell lines were treated with 0.5 mM (clear symbols)
or 2.0 mM (filled symbols) of each of the three BMAP-28 isomers, L-BMAP-28 (m, g), RI-BMAP-28 (#,N) and D-BMAP-28 (%, &) and analyzed for
membrane permeabilization using SYTOX. (A) L. major wt, (B) L. major ko, (C) L. major ko+. Incubation of cells with 0.5% Triton X-100 (filled diamonds)
were used as a positive control. Three complete biological replicates were performed and the average is shown, with standard deviations less than
5% for all values.
doi:10.1371/journal.pntd.0001141.g003
Figure 4. Induction of early apoptosis events in L. major strains after incubation with D-BMAP-28. L. major wt (black bars), L. major ko
(clear bars) and L. major ko+ (grey bars) were treated with 2 mM D-BMAP-28 for 0.5 hr, 1 hr, 2 hr, and 4 hr and then analyzed for caspase 3/7
activation. L. major wt cells treated with 16 mM staurosporine for the indicated period of time were used as positive control (striped bars). Each bar
represents the mean of four replicates; error bar represents the standard error of the mean.
doi:10.1371/journal.pntd.0001141.g004
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that these activities are conserved amongst all members of the
cathelicidin family. The demonstration that many HDPs,
including the cathelicidins, also function through modulation of
host immune responses [13,14,15,16,17,18] further supports their
potential as anti-infective therapeutics including anti-parasitic
pharmaceuticals.
BMAP-28, a 28 residue bovine cathelicidin HDP, has broad
spectrum antimicrobial activities that include antibiotic-resistant
bacterial clinical isolates and fungal pathogens [25] and induces
membrane permeabilization and cell death in human tumor cell
lines [25]. BMAP-28 also confers protection in various murine
bacterial challenge models [23,40] and reduces lethality to
staphylococcal sepsis in vivo [24,41].
As concerns have been raised regarding the therapeutic
potential of HDPs due to their stability in vivo [42], strategies for
improving HDP stability have been investigated primarily through
the substitution of D-amino acids at the chiral centers of the HDPs
[26,36]. Similarly, modification of HDPs through retro-inversion
by reversal of the peptide sequence and incorporation of D-amino
acids also represents an intriguing strategy for increasing the
therapeutic efficacy of HDPs [26]. Thus a comparative investiga-
tion of BMAP-28, D-BMAP-28 and RI-BMAP-28 appeared as a
logical choice for the investigation protease resistant HDP anti-
leishmanial therapeutics.
As anticipated from previous studies of other cathelicidins
[19,20,21,22], BMAP-28 has leishmanicidal activity against the
promastigote L. major Friedlin and the Seidman strains as
demonstated through a MTS assay of Leishmanial cell viability.
Importantly our results demonstrate that D- and RI-BMAP-28
were also effective antimicrobials against L. major Friedlin and
Seidman wild-type in a dose dependent manner. Interestingly, D-
BMAP-28 was the most effective direct antimicrobial against both
strains. This is perhaps less surprising as previous investigations
with enantiomeric antimicrobial peptides have demonstrated
equivalent or enhanced antimicrobial activities against both
Gram-positive and Gram-negative bacteria as compared to their
L-amino acid analogs [43,44,45]. RI-BMAP-28, which has
virtually identical protease resistance profiles to D-BMAP-28 and
similar seconday structure to L-BMAP-28 [26], also had improved
leishmanicidal activity against the L. major Friedlin strain as
compared to L-BMAP-28.
As a single therapeutic with immunomodulatory and leishma-
nicidal activites would be highly advantageous in the clinic we
sought to verify the immunomodulatory activities of the three
BMAP-28 isomers (Text S1). In addition to the chemotactic
activities previously demonstrated for BMAP-28 [24,25,40,46] and
its RI- and all D- isomers [26], all three peptides were able to
modulate chemokine secretion and inhibit LPS-mediated pro-
inflammatory responses. An investigation by Santamaria et al. has
also demonstrated the immunomodulatory potential of protease
resistant peptides as enantiomeric pEM-2, an all-D amino acid
derivative of a snake venom Lys49 phospholipase A2, significantly
reduced LPS-induced TNF-a secretion from murine macrophages
[44]. Thus, modification of HDPs by either inversion or retro-
inversion appears to be a logical methodology for extending the
biological half-lives of HDPs without undermining either leishma-
nicidal or immunodulatory activities of the peptide.
It has been demonstrated that the Leishmania surface metallo-
protease leishmanolysin confers protection to the organism from
the cytolytic properties of HDPs [20]. Leishmanolysin is the
Leishmania surface-localized, zinc-dependent metalloproteinase and
virulence factor, also known as GP63 or MSP [47,48,49].
Characterization of leishmanolysin has revealed that it is a neutral
site-specific endopeptidase which preferentially cleaves peptides on
the amino side of the recognition residue [50] and has a broad
range of substrates [50,51,52,53,54]. Previously, a L. major GP63
knockout mutant, L. major ko, was developed in which all 7 copies
Figure 5. Induction of late apoptosis events in L. major strains after incubation with D-BMAP-28. Quantitative colorimetric analysis of
DNA degradation in L. major wt (black bars), L. major ko (clear bars) and L. major ko+ (grey bars) after treatment with 2 mM D-BMAP-28 for 0.5 hr, 1 hr,
2 hr, 4 hr and 24 hr using the TUNEL assay. Cells treated with 16 mM staurosporine (STS) as well as DNase treated cell lysates were used as positive
controls. Each bar represents the mean of three replicates; error bar represents the standard error of the mean.
doi:10.1371/journal.pntd.0001141.g005
Effect BMAP-28 Peptides on Leishmania major Growth
www.plosntds.org 9 May 2011 | Volume 5 | Issue 5 | e1141Effect BMAP-28 Peptides on Leishmania major Growth
www.plosntds.org 10 May 2011 | Volume 5 | Issue 5 | e1141of GP63 were deleted [30]. As anticipated, the leishmanicidal
activities of RI- and D-BMAP-28 were independent of GP63
whereas L-BMAP-28 was less effective in the presence of the
leishmanolysin factor and more effective in the ko strain. These
results supported previous findings that the presence of leishma-
nolysin protects the parasites from the cytolytic effects of various
antimicrobial peptides through degradation [20]. Specifically,
leishmanolysin has been shown to degrade the peptide pexiganan
in the presence of zinc within a 15 min period [20]. Both L. major
wt and ko+ strains maintain these activities, which are absent from
L. major ko strain [20].
It is interesting that at a concentration of 0.5 mM D-BMAP-28
was the most effective antimicrobial against the ko mutant whereas
at 2 mM L-BMAP-28 was clearly the best peptide. As the
antimicrobial activities of L-BMAP-28 are retained or improved
following incorporation of D-amino acids it would be assumed that
these activities represent non-chiral mechanisms of action. Thus,
this may represent differences in the abilities of L- and D-BMAP-
28 to associate and/or form active complexes in a concentration-
dependent manner.
Differences were observed in the effectiveness of the peptides
between the L. major Friedlin and Seidman strains as the peptides
were more effective in the L. major Seidman strain than the Friedlin
strain at equimolar concentrations. Although this emphasizes the
importance of repeating such studies in several strains, the present
work clearly demonstrates that protease resistant HDPs appear to
have vastly improved leishmanicidal activities in comparison to
their L- amino acid analogs.
Members of the cathelicidin family appear to exert their
leishmanicidal activities through apoptotic and non-apoptotic
mechanism of action resulting in significant membrane disruption,
osmotic lysis and subsequent cell death [22,25]. Our electron
microscopy results demonstrated that all three BMAP-28 isomers
caused significant disruption of membrane integrity in L. major wt
cells similar to previous investigations of Hst5 [12] and bombinins
H2/H4 [36]. Ultimately resulting in osmotic instability, vacuolar
swelling, loss of cytosolic contents and eventual cell death.
Protegrin, was previous shown to induce a nonapoptotic cell
death in L. major, classified as annexin V negative, caspase 3/7
negative, Tunel assay negative and triggered a slow and steady
response upon SYTOX incubation [20,21]. Pexiganan, on the
other hand induces an apoptotic cell death in Leishmania classified
as annexin V positive, caspase 3/7 positive, Tunel assay positive
and triggers a sustained response upon SYTOX incubation
[20,21]. Therefore, we postulated that the various BMAP-28
isomers would act through either pathway.
We utilised a SYTOX assay, a caspase 3/7 assay and a Tunel
assay to classify the BMAP-28 induced cell death. The SYTOX
assay results indicated a rapid and sustained response which would
suggest an induction of an apoptotic response similar to that
induced by pexiganan [21]. We subsequently investigated the
caspase 3/7 activity and DNA laddering activity that resulted in
response to D-BMAP-28 incubation, the most effective of the
BMAP-28 peptides. There were minimal levels of caspase 3/7
activity in response to incubation with D-BMAP-28. Similarly
there was no indication of DNA laddering in the stages of this
induced response. This suggested a caspase-independent cell
death. It was not until we investigated the induced late stage
response to D-BMAP-28 that we were able to detect signs of
apoptosis. At 24 hr it was clear that the D-BMAP-28 peptide
induced apoptosis in all three cell strains. These results differ from
those recently reported for pexiganan, where a caspase dependent
apoptotic event was triggered early in response to peptide
incubation [21], instead a late apoptotic event was triggered in
response to incubation with D-BMAP-28.
Although the results from the L. major promastigote assays would
suggest that BMAP-28 isoforms present a promising Leishmanial
therapeutic candidate, this must be tempered with the under-
standing that it is the amastigote form of the parasite that causes
disease in mammals. Upon infection promastigotes invade the
macrophage cell where differentiate into amastigotes and take up
residence in the lysosomal vacuole of the cell. Importantly, the
amastigote differs dramatically both morphologically and meta-
bolically from the promastigote form.
Previous studies involving murine Brucella abotus infection
models have shown that antimicrobial peptides are able to enter
the murine macrophage cell, evading lysis by macrophage
enzymes and induce peptide mediated killing within a 24 hour
period [55]. Thus we created a macrophage infection assay that
mimicked mammalian infection to assess the activity of the
BMAP-28 peptides on the amastigote parasite. Macrophages
infected with wt parasites responded in a dose-dependent manner
to treatment with the BMAP-28 peptides. When repeated using ko
parasites to infect the macrophages, there were no major
differences between the activity of the L- form of the peptide
between wt and ko infections. As the leishmanolysin factor is
significantly downregulated in the amastigote form of the parasite
[56], leishmanolysin would be unable to impede the activity of the
L- form of the peptide to the same extent as in the case of
promastigotes. As anticipated, the D-form of the peptide, which
was also shown to be effective at clearance of murine Escherichia coli
infections upon prophylactic treatment [26], was more effective
against the L. major ko amastigotes as compared to the wt
amastigotes at the same concentration. The D- isoform was also
most effective at reducing L. major wt promastigote cell viability.
Apart from its proteolytic role, leishmanolysin also has a
number of other roles within the macrophage infection model that
may explain the differences in activities amongst the three peptides
between the wild-type and the ko amastigote strains. Leishmano-
lysin is involved in the direct interaction of promastigotes and the
macrophage receptors where it serves as a ligand for binding
macrophage complement [57,58], as well as generating an
additional epitope (C3bi) for binding to complement type 3
receptors [59]. Additionally, leishmanolysin ko mutants have
increased complement sensitivity and less lesion development
than wt parasites in mouse models of infection [30,60].
Currently the majority of research into novel anti-leishmanial
compounds and peptides focuses on their activities against the
promastigotes form of the parasite. Our results clearly demonstrate
the differences in activities of L-BMAP-28, D-BMAP-28 and RI-
BMAP-28 between promastigotes and amastigotes and address the
role of the leishmanolysin factor in reducing the activity of protease-
Figure 6. The effect of BMAP-28 isomers on intramacrophage L. major infection. (A) The figure displays images that were collected from
peritoneal macrophages infected with L. major Seidman wt strains for 24 h, and treated with L-, RI- and D-BMAP-28 at 0.5 mM for an additional 24 h.
Infected macrophages were stained with DAPI and examined under UV light with an upright fluorescent microscope, using 100 magnification. (B)
Peritoneal macrophages were infection with L. major Seidman wt (filled) and ko strains (open) for 24 h, and treated with L-, RI- and D-BMAP-28 at 0.5
and/or 2 mM for 48 h. Infections were stained with DAPI and parasite burden was quantified as an average of 100 macrophages, and expressed as a
percentage of the control infection. The average number of three complete biological replicates as well as the standard errors are shown. Paired T-
tests untreated vs treated indicated significance, where * p,0.05, **p,0.005, ***p,0.0005.
doi:10.1371/journal.pntd.0001141.g006
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BMAP-28 and its isomers, D-BMAP-28 and RI-BMAP-28, are
effective leishmanicidal compounds against promastigotes (insect
infective form) in vitro inducing cell membrane disruption culmi-
nating in a late stage apoptotic cell death response. Moreover the
BMAP-28 peptides were also effective at reducing amastigote cell
viability within a macrophage infection model. Importantly, our
results demonstrate that BMAP-28 is a promising template for the
development of anti-infective therapeutics targeting Leishmania.I ti s
imperative however that such design and development strategies
address compound activity against both the promastigote and the
amastigote form of the parasite.
Supporting Information
Figure S1 Inhibition of LPS-induced TNF-a secretion
from human PBMCs by L-, D- and RI-BMAP-28. PBMCs
were incubated with 1.5 mM of L-BMAP 28, RI-BMAP-28, D-
BMAP-28 or LL-37 (positive control) for 45 minutes before
treating with highly purified Pseudomonas aeruginosa lipopolysaccha-
ride (10 ng/ml). After 4 hours, TNF-a was measured in the
supernatants by ELISA. Black bar: PBMC incubated with LPS
alone. White bars: PBMC incubated with LL-37, L-BMAP 28, D-
BMAP 28 or RI-BMAP 28. The average of three complete
biological replicates are shown with standard errors.
(TIF)
Figure S2 The effect of BMAP-28 peptides on L. major
cells. Wild-type cells were (A) untreated or treated with (B) L-
BMAP-28, (C) RI-BMAP-28 or (D) D-BMAP-28 at 0.5 mM
concentrations for 4 hours prior to fixation for TEM analyses.
(TIF)
Table S1 The effect of BMAP-28 peptides on murine
derived macrophages. THP-1 cells were treated with 1 or
5 mM concentrations of L-, Ri or D-BMAP-28 for 24 or 72 hours.
A trypan blue assay assessed the resulting cell viability and was
recorded as a percentage. D- and RI-BMAP-28 retain immuno-
modulatory activities of L-BMAP-28. Although it was demon-
strated that the D- and RI-BMAP-28 have retained or improved
leishmanicidal activity of the parent peptide we also sought to
investigate whether BMAP-28 and its protease resistant isomers
may have the ability to modulate host immune responses including
TNF-a mediated inflammatory responses. The D- and RI-BMAP-
28 isomers retained the ability to induce the release of the
chemokine MCP-1 in human PBMCs in a concentration-
dependent manner similar to L-BMAP-28 (data not shown). All
three peptides were also tested for their ability to inhibit LPS-
induced TNF-a secretion in PBMCs. In three separate experi-
ments, however, all of the BMAP-28 isomers strongly inhibited the
induction of TNF-a secretion by LPS to the same degree as the
human cathelicidin LL-37 (Figure S1). None of the BMAP-28
isomers directly induced TNF-a secretion.
(PDF)
Text S1 D- and RI-BMAP-28 retain immunomodulatory
activities of L-BMAP-28.
(DOC)
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